Omeros Cash on Hand 2010-2025 | OMER

Omeros cash on hand from 2010 to 2025. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at any time, and investments maturing in one year or less that are highly liquid and therefore regarded as cash equivalents and reported with or near cash line items.
Omeros Annual Cash on Hand
(Millions of US $)
2024 $90
2023 $172
2022 $195
2021 $157
2020 $135
2019 $61
2018 $60
2017 $84
2016 $45
2015 $28
2014 $7
2013 $14
2012 $22
2011 $25
2010 $42
2009 $60
Omeros Quarterly Cash on Hand
(Millions of US $)
2025-03-31 $52
2024-12-31 $90
2024-09-30 $123
2024-06-30 $159
2024-03-31 $230
2023-12-31 $172
2023-09-30 $310
2023-06-30 $341
2023-03-31 $371
2022-12-31 $195
2022-09-30 $221
2022-06-30 $123
2022-03-31 $142
2021-12-31 $157
2021-09-30 $50
2021-06-30 $74
2021-03-31 $100
2020-12-31 $135
2020-09-30 $154
2020-06-30 $16
2020-03-31 $54
2019-12-31 $61
2019-09-30 $27
2019-06-30 $32
2019-03-31 $47
2018-12-31 $60
2018-09-30 $55
2018-06-30 $88
2018-03-31 $73
2017-12-31 $84
2017-09-30 $87
2017-06-30 $30
2017-03-31 $34
2016-12-31 $45
2016-09-30 $47
2016-06-30 $21
2016-03-31 $13
2015-12-31 $28
2015-09-30 $35
2015-06-30 $51
2015-03-31 $70
2014-12-31 $7
2014-09-30 $22
2014-06-30 $37
2014-03-31 $52
2013-12-31 $14
2013-09-30 $9
2013-06-30 $20
2013-03-31 $13
2012-12-31 $22
2012-09-30 $31
2012-06-30 $7
2012-03-31 $18
2011-12-31 $25
2011-09-30 $33
2011-06-30 $37
2011-03-31 $44
2010-12-31 $42
2010-09-30 $35
2010-06-30 $42
2010-03-31 $51
2009-12-31 $60
2009-09-30 $4
2009-06-30
2009-03-31
Sector Industry Market Cap Revenue
Medical Medical Products Manufacturing $0.198B $0.000B
Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders.
Stock Name Country Market Cap PE Ratio
Abbott Laboratories (ABT) United States $240.237B 28.89
Boston Scientific (BSX) United States $154.040B 38.56
Stryker (SYK) United States $147.507B 30.84
EssilorLuxottica (ESLOY) France $130.320B 0.00
Medtronic (MDT) Ireland $110.401B 15.65
Lonza Group Ag (LZAGY) Switzerland $51.194B 0.00
Haleon (HLN) United Kingdom $47.171B 26.90
ResMed (RMD) United States $37.523B 28.18
Agilent Technologies (A) United States $33.417B 21.78
GE HealthCare Technologies (GEHC) United States $32.959B 15.65
Terumo (TRUMY) Japan $27.294B 35.45
Koninklijke Philips (PHG) Netherlands $23.014B 16.15
Insulet (PODD) United States $21.880B 85.88
Zimmer Biomet Holdings (ZBH) United States $18.269B 11.73
Baxter (BAX) United States $15.698B 11.72
Smith & Nephew SNATS (SNN) United Kingdom $13.073B 0.00
Demant (WILYY) Denmark $9.110B 0.00
Sunny Optical Technology (SNPTF) China $8.561B 0.00
Bio-Rad Laboratories (BIO) United States $6.474B 22.53
Lantheus Holdings (LNTH) United States $5.601B 14.13
Prestige Consumer Healthcare (PBH) United States $4.184B 18.69
Perrigo (PRGO) Ireland $3.678B 9.32
Haemonetics (HAE) United States $3.510B 15.99
Shandong Weigao Medical Polymer (SHWGF) China $3.459B 0.00
ICU Medical (ICUI) United States $3.221B 23.75
Envista Holdings (NVST) United States $3.210B 26.68
GN Store Nord (GNNDY) Denmark $2.346B 19.43
QuidelOrtho (QDEL) United States $1.939B 13.34
LeMaitre Vascular (LMAT) United States $1.916B 42.83
AtriCure (ATRC) United States $1.621B 0.00
Acuren (TIC) United States $1.311B 0.00
AdaptHealth (AHCO) United States $1.182B 12.00
Neogen (NEOG) United States $1.070B 13.69
Green Thumb Industries (GTBIF) United States $1.063B 23.91
BioLife Solutions (BLFS) United States $1.036B 0.00
Phibro Animal Health (PAHC) United States $1.004B 12.83
Kestra Medical Technologies (KMTS) United States $0.906B 0.00
InMode (INMD) Israel $0.870B 8.76
CeriBell (CBLL) United States $0.710B 0.00
Evolus (EOLS) United States $0.620B 0.00
Owens & Minor (OMI) United States $0.578B 4.79
Maravai LifeSciences Holdings (MRVI) United States $0.568B 0.00
Curaleaf Holdings (CURLF) Canada $0.519B 0.00
Valneva SE (VALN) France $0.477B 0.00
Capricor Therapeutics (CAPR) United States $0.423B 0.00
Surmodics (SRDX) United States $0.415B 0.00
Tilray Brands (TLRY) Canada $0.384B 0.00
VAREX IMAGING (VREX) United States $0.328B 12.05
SNDL (SNDL) Canada $0.326B 0.00
SEMPERIT AG HLD (SEIGY) Austria $0.300B 0.00
Sanuwave Health (SNWV) United States $0.279B 0.00
Viemed Healthcare (VMD) United States $0.274B 23.10
Cerus (CERS) United States $0.262B 0.00
Sanara MedTech (SMTI) United States $0.253B 0.00
ZimVie (ZIMV) United States $0.247B 11.22
Brainsway (BWAY) Israel $0.232B 61.30
Canopy Growth (CGC) Canada $0.230B 0.00
Quanterix (QTRX) United States $0.229B 0.00
Cresco Labs (CRLBF) United States $0.228B 0.00
OraSure Technologies (OSUR) United States $0.224B 0.00
Aurora Cannabis (ACB) Canada $0.224B 66.33
Biote (BTMD) United States $0.218B 6.14
TriSalus Life Sciences (TLSI) United States $0.198B 0.00
Organigram Global (OGI) Canada $0.182B 0.00
Utah Medical Products (UTMD) United States $0.181B 14.74
High Tide (HITI) Canada $0.177B 0.00
Verano Holdings (VRNOF) United States $0.175B 0.00
Exagen (XGN) United States $0.150B 0.00
Vireo Growth (VREOF) United States $0.131B 0.00
FitLife Brands (FTLF) United States $0.121B 14.84
Jin Medical (ZJYL) China $0.103B 0.00
Veru (VERU) United States $0.098B 0.00
Oramed Pharmaceuticals (ORMP) United States $0.089B 0.00
Fonar (FONR) United States $0.088B 11.32
Apyx Medical (APYX) United States $0.086B 0.00
Quipt Home Medical (QIPT) United States $0.086B 0.00
MacroGenics (MGNX) United States $0.085B 0.00
TerrAscend (TSNDF) Canada $0.078B 0.00
Zynex (ZYXI) United States $0.076B 0.00
Cytosorbents (CTSO) United States $0.075B 0.00
InterCure (INCR) Israel $0.069B 0.00
Agape ATP (ATPC) $0.065B 0.00
ImmuCell (ICCC) United States $0.062B 0.00
Jushi Holdings (JUSHF) United States $0.057B 0.00
Nephros (NEPH) United States $0.044B 59.43
Modular Medical (MODD) United States $0.043B 0.00
United-Guardian (UG) United States $0.037B 12.89
Rockwell Medical (RMTI) United States $0.030B 0.00
Safety Shot (SHOT) United States $0.023B 0.00
Allurion Technologies (ALUR) United States $0.018B 0.00
Cellectar Biosciences (CLRB) United States $0.018B 0.00
Flora Growth (FLGC) United States $0.015B 0.00
INLIF (INLF) $0.014B 0.00
Meihua Medical Technologies (MHUA) China $0.013B 0.00
Trinity Biotech (TRIB) Ireland $0.013B 0.00
Senestech (SNES) United States $0.007B 0.00
Innovative Eyewear (LUCY) United States $0.007B 0.00
IM Cannabis (IMCC) Canada $0.006B 0.00
GlucoTrack (GCTK) United States $0.003B 0.00
Akanda (AKAN) Canada $0.002B 0.00
Sharps Technology (STSS) United States $0.000B 0.00
InVivo Therapeutics Holdings (NVIVQ) United States $0.000B 0.00